TREACE MEDICAL CONCEPTS INC (TMCI)
US89455T1097 - Common Stock
TMCI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. While TMCI seems to be doing ok healthwise, there are quite some concerns on its profitability. TMCI is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TMCI has reported negative net income.
In the past year TMCI has reported a negative cash flow from operations.
TMCI had negative earnings in each of the past 5 years.
In the past 5 years TMCI always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of TMCI (-28.89%) is comparable to the rest of the industry.
TMCI has a Return On Equity (-58.65%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.89% | ||
| ROE | -58.65% | ||
| ROIC | N/A |
ROA(3y)-20.43%
ROA(5y)-17.61%
ROE(3y)-42.96%
ROE(5y)-163.9%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TMCI has a better Gross Margin (80.61%) than 93.05% of its industry peers.
TMCI's Gross Margin has been stable in the last couple of years.
TMCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 80.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.25%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TMCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
TMCI has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, TMCI has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.18 indicates that TMCI is not a great score, but indicates only limited risk for bankruptcy at the moment.
TMCI has a Altman-Z score of 2.18. This is in the better half of the industry: TMCI outperforms 60.96% of its industry peers.
A Debt/Equity ratio of 0.51 indicates that TMCI is somewhat dependend on debt financing.
The Debt to Equity ratio of TMCI (0.51) is worse than 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.18 |
ROIC/WACCN/A
WACC9.09%
2.3 Liquidity
TMCI has a Current Ratio of 4.12. This indicates that TMCI is financially healthy and has no problem in meeting its short term obligations.
TMCI has a Current ratio of 4.12. This is in the better half of the industry: TMCI outperforms 65.78% of its industry peers.
TMCI has a Quick Ratio of 2.98. This indicates that TMCI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.98, TMCI is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.12 | ||
| Quick Ratio | 2.98 |
3. Growth
3.1 Past
TMCI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.99%.
Looking at the last year, TMCI shows a quite strong growth in Revenue. The Revenue has grown by 16.13% in the last year.
TMCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 48.27% yearly.
EPS 1Y (TTM)-18.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.71%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y48.28%
Revenue growth 5YN/A
Sales Q2Q%10.62%
3.2 Future
The Earnings Per Share is expected to grow by 11.00% on average over the next years. This is quite good.
TMCI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.06% yearly.
EPS Next Y-16.48%
EPS Next 2Y2.64%
EPS Next 3Y4.58%
EPS Next 5Y11%
Revenue Next Year12.03%
Revenue Next 2Y10.18%
Revenue Next 3Y9.96%
Revenue Next 5Y14.06%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TMCI. In the last year negative earnings were reported.
Also next year TMCI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.64%
EPS Next 3Y4.58%
5. Dividend
5.1 Amount
TMCI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TREACE MEDICAL CONCEPTS INC
NASDAQ:TMCI (11/21/2024, 8:00:01 PM)
After market: 7.91 -0.03 (-0.38%)7.94
-0.04 (-0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap494.66M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.89% | ||
| ROE | -58.65% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 80.61% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.12 | ||
| Quick Ratio | 2.98 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-18.99%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-16.48%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)16.13%
Revenue growth 3Y48.28%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y